Home » Topics » Disease categories and therapies » Urology

Urology
RSS

New compound for BPH in active preclinical development at Merck & Co. and Synaptic

April 20, 1999

New frontiers in gene therapy: treatment of erectile dysfunction

April 20, 1999

(+)-SNAP-6991 discovered at Synaptic and Merck as orally active, uroselective alpha1a blocker

April 5, 1999

New antimuscarinic piperidine derivative from Taisho inhibits bladder contractions

April 1, 1999

Pharmacokinetics and pharmacodynamics of VPA-985 in healthy volunteers

March 31, 1999

Aminoethylphenoxyacetic acids for urinary lithiasis in development at Kissei

March 30, 1999

U.S. patent issues to Vivus for second-generation ED therapeutic

March 29, 1999

Asahi Chemical launches alpha-adrenoceptor antagonist in Japan

March 26, 1999

Potassium and/or chloride channel modulators claimed for incontinence and IBS

March 25, 1999

Dainippon's AH-9700 is an excellent candidate for treatment of urge incontinence

March 25, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....